Previous Page  11 / 28 Next Page
Information
Show Menu
Previous Page 11 / 28 Next Page
Page Background

Olaparib improves PFS and ORR in gBRCAm MBC

OLIMPIA

Olaparib

TPC (Cape, VNR, Eribulin)

gBRCAm MBC

<2 previous lines

Robson ME. NEJM 2017

1.0

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0.0

Progression Free Survival

Time from randomisation (months)

14

12

10

8 6 4 2 0

16 18 20 22 24 26 28

Olaparib 300 mg bd (N=205)

TPC (N=97)

Olaparib

TPC

n

205

97

Median PFS

7.0 m 4.2 m

HR =

0.58

(0.43, 0.80)

p=0.0009

Olaparib

TPC

n

167

66

ORR

59.9% 28.8%

Randomise 2:1

N=302

Stratification by

Prior chemo regimens MBC

Hormonal receptor status

Prior platinum therapy